IHCAP

Investigating Hereditary Cancer Predisposition – a combined genomics approach

Coordinatore	THE CHANCELLOR, MASTERS AND SCHOLARS OF THE UNIVERSITY OF CAMBRIDGE    more Spiacenti, non ci sono informazioni su questo coordinatore. Contattare Fabio per maggiori infomrazioni, grazie.
Nazionalità Coordinatore	United Kingdom [UK]
Totale costo	1˙446˙560 €
EC contributo	1˙446˙560 €
Programma	FP7-IDEAS-ERC Specific programme: "Ideas" implementing the Seventh Framework Programme of the European Community for research, technological development and demonstration activities (2007 to 2013)
Code Call	ERC-2012-StG_20111109
Funding Scheme	ERC-SG
Anno di inizio	2013
Periodo (anno-mese-giorno)	2013-05-01   -   2018-04-30

 Partecipanti

#	participant	country	role	EC contrib. [€]
1	THE CHANCELLOR, MASTERS AND SCHOLARS OF THE UNIVERSITY OF CAMBRIDGE  Organization address address: The Old Schools, Trinity Lane city: CAMBRIDGE postcode: CB2 1TN contact info Titolo: Dr. Nome: Marc Derek Cognome: Tischkowitz Email: send email Telefono: +44 (0)1223 348735	UK (CAMBRIDGE)	hostInstitution	1˙446˙560.00
2	THE CHANCELLOR, MASTERS AND SCHOLARS OF THE UNIVERSITY OF CAMBRIDGE  Organization address address: The Old Schools, Trinity Lane city: CAMBRIDGE postcode: CB2 1TN contact info Titolo: Ms. Nome: Renata Cognome: Schaeffer Email: send email Telefono: +44 1223 333543 Fax: +44 1223 332988	UK (CAMBRIDGE)	hostInstitution	1˙446˙560.00

Mappa

 Word cloud

Esplora la "nuvola delle parole (Word Cloud) per avere un'idea di massima del progetto.

 Obiettivo del progetto (Objective)

'Background: Hereditary cancer is an important cause of morbidity and mortality and over the last 20 years, the majority of highly penetrant risk alleles such as BRCA1, BRCA2 in breast cancer and APC, MLH1, MSH2 in colon cancer have been identified. However, there are many men and women who have a strong family of cancer for whom we cannot provide answers because no mutation is found in known genes. Objectives: i) To identify new candidate breast cancer susceptibility loci by an innovative combination of exome sequencing technology and genome-wide allele-specific expression analysis of BRCA1/2-negative women with strong family histories of BC. This approach will be complemented by exomic sequencing of carefully selected matched cohorts of women with unilateral and bilateral breast cancer on whom extensive demographic and clinical data is available. ii) To study selected gene candidates in more detail at the DNA, RNA and protein level. iii) To apply the knowledge gained in the genomic study of breast cancer to other cancer predisposition syndromes. Significance: At present, the new combined approach of EST and ASE has several advantages over the alternative option of whole genome sequencing in the identification of rare functional variants; not only will EST plus ASE be cheaper and faster than a whole genome sequencing approach, but it will also allow us to explore the potentially unappreciated roles of allelic silencing (through regulatory or epigenetic variants) in cancer susceptibility, which would not be captured using genomic sequencing in isolation. We will commence the project with breast cancer families and then apply the same approach to other types of hereditary cancers. This proposal is focused on individuals who face a truly high risk for cancer but for whom predictive information is lacking and therefore this proposal is likely to have a direct translational benefit.'